Drug Profile
Gamma amino butyric acid controlled-release - Diamyd Medical
Alternative Names: GABA - Diamyd; Gamma-amino-butyric-acid-Diamyd; Oral GABA Therapy - Diamyd; RemygenLatest Information Update: 15 May 2023
Price :
$50
*
At a glance
- Originator Diamyd Medical AB
- Developer Diamyd Medical AB; Uppsala University Hospital
- Class Amines; Antihyperglycaemics; Butyric acids; Small molecules
- Mechanism of Action GABA receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Type 1 diabetes mellitus
Most Recent Events
- 10 May 2023 Topline adverse events data from phase I/II ReGenerate-1 trial in Type 1 diabetes mellitus released by Diamyd Medical
- 05 Apr 2023 Before March 2023, Diamyd Medical received patent protection in the US and Japan for GABA formulation Remygen®
- 27 Mar 2023 Pharmacokinetics data from a phase I/II trial in Diabetes mellitus released by Diamyd Medical